NEW YORK (GenomeWeb) – Foundation Medicine officials this week detailed several efforts the firm intends to take on in 2016 including plans to launch its FoundationAct clinical circulating tumor DNA test and to submit its first companion diagnostic test to the US Food and Drug Administration.

In addition, the firm plans to work towards a universal companion diagnostic, launch its clinical tests further outside the US with Roche, look for a new facility outside of Cambridge, and expand reimbursement for its clinical tests.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.